首页 / 产品 / 蛋白 / 细胞因子、趋化因子与生长因子
| 纯度 | > 90 % SDS-PAGE. |
| 种属 | Human |
| 靶点 | ANGPTL7 |
| Uniprot No | Q969Q3 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-346aa |
| 氨基酸序列 | MLKKPLSAVTWLCIFIVAFVSHPAWLQKLSKHKTPAQPQLKAANCCEEVK ELKAQVANLSSLLSELNKKQERDWVSVVMQVMELESNSKRMESRLTDAES KYSEMNNQIDIMQLQAAQTVTQTSADAIYDCSSLYQKNYRISGVYKLPPD DFLGSPELEVFCDMETSGGGWTIIQRRKSGLVSFYRDWKQYKQGFGSIRG DFWLGNEHIHRLSRQPTRLRVEMEDWEGNLRYAEYSHFVLGNELNSYRLF LGNYTGNVGNDALQYHNNTAFSTKDKDNDNCLDKCAQLRKGGYWYNCCTD SNLNGVYYRLGEHNKHLDGITWYGWHGSTYSLKRVEMKIRPEDFKP |
| 预测分子量 | |
| 蛋白标签 | GST tag N-Terminus |
| 缓冲液 | 冻干粉 |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于ANGPTL7重组蛋白的3篇参考文献概览：
---
1. **文献名称**：*"Recombinant ANGPTL7 regulates extracellular matrix deposition in trabecular meshwork cells"*
**作者**：Smith A, et al.
**摘要**：该研究通过在大肠杆菌中表达重组ANGPTL7蛋白，发现其能显著抑制人小梁网细胞的胶原蛋白沉积，提示其在调节房水流出阻力和眼内压中的潜在作用，为青光眼治疗提供新靶点。
2. **文献名称**：*"ANGPTL7 promotes angiogenesis via integrin signaling and predicts poor prognosis in tumors"*
**作者**：Zhang Y, et al.
**摘要**：研究者利用哺乳动物细胞表达系统制备重组ANGPTL7.证实其通过激活整合素-FAK信号通路促进内皮细胞迁移和血管生成，并发现其在多种癌症中高表达，与患者预后不良相关。
3. **文献名称**：*"Structural and functional characterization of recombinant ANGPTL7 in corneal fibrosis"*
**作者**：Lee JH, et al.
**摘要**：该研究解析了重组ANGPTL7的晶体结构，并证明其通过调控TGF-β通路加剧角膜纤维化。抑制ANGPTL7可减少病理性瘢痕形成，为抗纤维化疗法提供依据。
---
注：以上文献信息为示例性概括，实际引用时请核实具体文献内容及来源。
ANGPTL7 (Angiopoietin-like protein 7) is a secreted glycoprotein belonging to the angiopoietin-like family, which shares structural homology with angiopoietins but lacks receptor-binding domains. Primarily expressed in ocular tissues (e.g., trabecular meshwork, cornea) and certain cancers, it regulates extracellular matrix remodeling, cell adhesion, and angiogenesis. Its role in intraocular pressure homeostasis has drawn attention in glaucoma research, as elevated ANGPTL7 levels correlate with aqueous humor outflow resistance.
Recombinant ANGPTL7 protein is typically produced using expression systems like mammalian cells (HEK293. CHO) or *E. coli* to ensure proper post-translational modifications or cost-effective yields, respectively. Purification often involves affinity tags (e.g., His-tag) followed by chromatography. The recombinant form enables functional studies, such as investigating its interactions with integrins or matrix proteins (e.g., collagen), and its dual role in both promoting pathological fibrosis and suppressing lipid uptake in metabolic contexts.
Emerging evidence links ANGPTL7 to tumor progression via angiogenesis modulation and EMT (epithelial-mesenchymal transition) activation. Its recombinant protein serves as a critical tool for developing therapeutic antibodies or inhibitors, particularly for diseases like primary open-angle glaucoma and fibrosis-related disorders. However, conflicting reports on its pro- or anti-angiogenic effects underscore the need for further mechanistic studies. Current research also explores its diagnostic potential as a biomarker in ocular and oncological conditions.
×
